Methods of using IL-31 monoclonal antibodies to reduce inflammation

• US 8,017,122 B2
• Filed: 04/08/2009
• Issued: 09/13/2011
• Est. Priority Date: 05/06/2005
• Status: Active Grant

• Current Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Original Assignee: Zymogenetics Incorporated (Bristol-Myers Squibb Company)
• Inventors: Rene, Shirley, Siadak, Anthony W., Bilsborough, Janine
• Primary Examiner(s): MERTZ, PREMA MARIA
• Application Number:
  US12/420,747
• Publication Number:
  US 20090220417A1
• Time in Patent Office: 888 Days
• Field of Search: None
• US Class Current: 424/145.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 17/04 Antipruritics
• CPC Class Codes: A61P 17/14 for baldness or alopecia
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 16/244 Interleukins [IL]
• CPC Class Codes: C07K 2317/21 from primates, e.g. man
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/34 Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C07K 2317/92 Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention further provides the hybridomas that generate the monoclonal antibodies.

Claims

1. A method of reducing inflammation in a mammal with a skin or epidermal condition having increased infiltration of cutaneous lymphocyte antigen (CLA+) T cells comprising administering to the mammal a monoclonal antibody or antibody fragment thereof, wherein the monoclonal antibody is produced by the hybridoma deposited with the American Type Culture Collection having the ATCC Patent Deposit Designation selected from the group consisting of:

a) ATCC Patent Deposit Designation PTA-6815;

b) ATCC Patent Deposit Designation PTA-6816;

c) ATCC Patent Deposit Designation PTA-6829;

d) ATCC Patent Deposit Designation PTA-6830;

e) ATCC Patent Deposit Designation PTA-6831;

f) ATCC Patent Deposit Designation PTA-6871;

g) ATCC Patent Deposit Designation PTA-6872;

h) ATCC Patent Deposit Designation PTA-6875; and

i) ATCC Patent Deposit Designation PTA-6873,

wherein the polypeptide consists of amino acid residues 27 to 164 of SEQ ID NO;

2, and wherein the inflammation is reduced.

2. The method according to claim 1, wherein the monoclonal antibody or antibody fragment neutralizes the interaction of the polypeptide with a receptor polypeptide comprising the amino acid sequence of SEQ ID NO:

5.

3. The method of claim 1, wherein the monoclonal antibody or antibody fragment comprises a radionuclide, enzyme, substrate, cofactor, fluorescent marker, chemiluminescent marker, peptide tag, magnetic particle, or toxin.

4. The method of claim 1, wherein the monoclonal antibody or antibody fragment comprises PEG.

5. The method of claim 1, wherein the monoclonal antibody or antibody fragment is selected from the group consisting of:

a) a chimeric antibody or antibody fragment;

b) a humanized antibody or antibody fragment; and

c) a Fab molecule; and

d) a F(ab′

)₂ molecule.

6. A method of reducing inflammation in a mammal with a skin or epidermal condition having increased infiltration of cutaneous lymphocyte antigen (CLA+) T cells comprising administering to the mammal a monoclonal antibody or antibody fragment thereof that is capable of inhibiting the binding of a polypeptide to a receptor, wherein the monoclonal antibody is produced by the hybridoma deposited with the American Type Culture Collection having the ATCC Patent Deposit Designation selected from the group consisting of:

a) ATCC Patent Deposit Designation PTA-6815;

b) ATCC Patent Deposit Designation PTA-6816;

c) ATCC Patent Deposit Designation PTA-6829;

d) ATCC Patent Deposit Designation PTA-6830;

e) ATCC Patent Deposit Designation PTA-6831;

f) ATCC Patent Deposit Designation PTA-6871;

g) ATCC Patent Deposit Designation PTA-6872;

h) ATCC Patent Deposit Designation PTA-6875; and

i) ATCC Patent Deposit Designation PTA-6873,

wherein the polypeptide consists of amino acid residues 27 to 164 of SEQ ID NO;

2, wherein the receptor is the IL-31RA receptor of SEQ ID NO;

5, and wherein the inflammation is reduced.

7. The method of claim 6, wherein the monoclonal antibody or antibody fragment comprises a radionuclide, enzyme, substrate, cofactor, fluorescent marker, chemiluminescent marker, peptide tag, magnetic particle, or toxin.

8. The method of claim 6, wherein the monoclonal antibody or antibody fragment comprises PEG.

9. The method of claim 6, wherein the monoclonal antibody or antibody fragment is selected from the group consisting of:

a) a chimeric antibody or antibody fragment;

b) a humanized antibody or antibody fragment; and

c) a Fab molecule; and

d) a F(ab′

)₂ molecule.

10. A method of reducing pruritis in a mammal with a skin or epidermal condition having increased infiltration of cutaneous lymphocyte antigen (CLA+) T cells comprising administering to the mammal a monoclonal antibody or antibody fragment thereof, wherein the monoclonal antibody is produced by the hybridoma deposited with the American Type Culture Collection having the ATCC Patent Deposit Designation selected from the group consisting of:

a) ATCC Patent Deposit Designation PTA-6815;

b) ATCC Patent Deposit Designation PTA-6816;

c) ATCC Patent Deposit Designation PTA-6829;

d) ATCC Patent Deposit Designation PTA-6830;

e) ATCC Patent Deposit Designation PTA-6831;

f) ATCC Patent Deposit Designation PTA-6871;

g) ATCC Patent Deposit Designation PTA-6872;

h) ATCC Patent Deposit Designation PTA-6875; and

i) ATCC Patent Deposit Designation PTA-6873,

wherein the polypeptide consists of amino acid residues 27 to 164 of SEQ ID NO;

2, and wherein the pruritis is reduced.

11. The method according to claim 10, wherein the monoclonal antibody or antibody fragment neutralizes the interaction of the polypeptide with a receptor polypeptide comprising the amino acid sequence of SEQ ID NO:

5.

12. The method of claim 10, wherein the monoclonal antibody or antibody fragment comprises a radionuclide, enzyme, substrate, cofactor, fluorescent marker, chemiluminescent marker, peptide tag, magnetic particle, or toxin.

13. The method of claim 10, wherein the monoclonal antibody or antibody fragment comprises PEG.

14. The method of claim 10, wherein the monoclonal antibody or antibody fragment is selected from the group consisting of:

a) a chimeric antibody or antibody fragment;

b) a humanized antibody or antibody fragment; and

c) a Fab molecule; and

d) a F(ab′

)₂ molecule.

15. A method of reducing pruritis in a mammal with a skin or epidermal condition having increased infiltration of cutaneous lymphocyte antigen (CLA+) T cells comprising administering to the mammal a monoclonal antibody or antibody fragment thereof that is capable of inhibiting the binding of a polypeptide to a receptor, wherein the monoclonal antibody is produced by the hybridoma deposited with the American Type Culture Collection having the ATCC Patent Deposit Designation selected from the group consisting of:

a) ATCC Patent Deposit Designation PTA-6815;

b) ATCC Patent Deposit Designation PTA-6816;

c) ATCC Patent Deposit Designation PTA-6829;

d) ATCC Patent Deposit Designation PTA-6830;

e) ATCC Patent Deposit Designation PTA-6831;

f) ATCC Patent Deposit Designation PTA-6871;

g) ATCC Patent Deposit Designation PTA-6872;

h) ATCC Patent Deposit Designation PTA-6875; and

i) ATCC Patent Deposit Designation PTA-6873,

wherein the polypeptide consists of amino acid residues 27 to 164 of SEQ ID NO;

2, wherein the receptor is the IL-31RA receptor of SEQ ID NO;

5, and wherein the pruritis is reduced.

16. The method of claim 15, wherein the monoclonal antibody or antibody fragment comprises a radionuclide, enzyme, substrate, cofactor, fluorescent marker, chemiluminescent marker, peptide tag, magnetic particle, or toxin.

17. The method of claim 15, wherein the monoclonal antibody or antibody fragment comprises PEG.

18. The method of claim 15, wherein the monoclonal antibody or antibody fragment is selected from the group consisting of:

a) a chimeric antibody or antibody fragment;

b) a humanized antibody or antibody fragment; and

c) a Fab molecule; and

d) a F(ab′

)₂ molecule.